Improving Health and Employment Outcomes Through Workplace Opioid Policies
NCT05387408 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 4939
Last updated 2024-10-04
Summary
Evaluate the feasibility of implementing workplace opioid guidelines in the construction trades; define and collect measures of implementation and efficacy. The investigators will implement the intervention in three local union health funds, evaluate the implementation using the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework, and collect the data needed to measure the efficacy of health changes due to implementation of the intervention (workplace opioid guidelines). This is only a feasibility trial in preparation for conducting an randomized control trial. For the efficacy trial, the investigators will measure pre-post health change using two data sources: 1) administrative health claims and electronic member work hours, and 2) worker/member surveys. To monitor implementation of the intervention, the investigators will measure changes made to the health funds opioid prevention program through qualitative interviews with the health fund manager and through worker surveys for worker awareness and use of the health fund program changes pre-post implementation. The efficacy outcomes for the administrative health (and pharmacy) claims and work hours record will measure opioid prescriptions, chronic opioid use, and OUD in health claims and pharmacy data (details below). The efficacy outcomes for the worker surveys will record changes in misuse of opioids, change in missed days/work productivity, change in attitudes toward seeking help if worker was struggling with opioid misuse, and awareness and use of health fund programs (i.e. employee assistance programs, healthcare recovery services). the investigators will collect data at baseline and and after 6 months for the study of implementation and efficacy (a pre/post design, one-arm trial).
Conditions
- Opioid-Related Disorders
Interventions
- BEHAVIORAL
-
Best Practice Health and Employment Opioid-related Policies
The intervention will include information to promote policies and programs to prevent opioid abuse and aid recovery such as drug testing for opioids, health and employee assistance programs, job accommodations, and education to deliver training to prevent opioid use, and prevent stigma.
Sponsors & Collaborators
-
Washington University School of Medicine
lead OTHER
Principal Investigators
-
Ann Marie Dale, Ph.D · Washington University School of Medicine
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-05-31
- Primary Completion
- 2023-03-01
- Completion
- 2023-03-01
Countries
- United States
Study Locations
More Related Trials
-
A Patient-Centered Intervention to Improve Opioid Safety
NCT02791399 ·Status: COMPLETED ·Phase: NA
-
Application of Economics & Social Psychology to Improve Opioid Prescribing Safety (AESOPS): R21 Pilot Phase
NCT03773484 ·Status: COMPLETED ·Phase: NA
-
Pilot Trial of Opioid Taper Support
NCT01883882 ·Status: COMPLETED ·Phase: NA
-
Comparing State Payer Strategies to Prevent Unsafe Opioid Prescribing
NCT03932799 ·Status: COMPLETED
-
Treatment Study Using Depot Naltrexone (1/6) Philadelphia Coord/Data Mgmt Site
NCT00781898 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Health Outcomes From Opioid Therapy for Chronic Pain
NCT00495404 ·Status: COMPLETED ·Phase: NA
-
Improved Treatment for Patients With Long-term Opioid Therapy for Non-cancer Pain in Primary Care
NCT06856733 ·Status: RECRUITING ·Phase: NA
-
Community Pharmacy-Based Prescription Drug Monitoring Program Opioid Risk Assessment Tool
NCT05706311 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Incentivizing Buprenorphine-Naloxone Initiation in Emergency Departments
NCT03821103 ·Status: COMPLETED ·Phase: NA
-
Repeated-dose Behavioral Intervention to Reduce Opioid Overdose
NCT03838510 ·Status: COMPLETED ·Phase: NA
-
The Impact of Co-Dispensing Naloxone to Patients Prescribed Chronic Opioid Therapy
NCT03337100 ·Status: COMPLETED ·Phase: NA
-
Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075
NCT03248947 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Opioid Rotation From Morphine to Methadone in Treatment of Non-malignant Pain
NCT00356083 ·Status: COMPLETED ·Phase: PHASE3
-
Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone
NCT05093309 ·Status: COMPLETED ·Phase: NA
-
Pain and Opioid Management in Older Adults
NCT05037682 ·Status: RECRUITING ·Phase: NA
-
Naltrexone in AUD Reward Drinkers
NCT05028062 ·Status: RECRUITING ·Phase: PHASE4
-
PRescribing INterventions for Chronic Pain Via the Electronic Health Record Study - Current Opioid-User Population
NCT04601480 ·Status: COMPLETED ·Phase: NA
-
The Impact of a Web-Based Naloxone Intervention Under Standing Orders to Patients Prescribed Chronic Opioid Therapy
NCT03337009 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)
NCT04464980 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298 ·Status: COMPLETED ·Phase: PHASE2
-
Behavioral Naltrexone Therapy for Promoting Adherence to Oral Naltrexone vs Extended Release Injectable Depot Naltrexone
NCT00577408 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence
NCT03015246 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder
NCT05011266 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Employment-Based Depot Naltrexone Clinical Trial
NCT00684788 ·Status: COMPLETED ·Phase: PHASE2
-
Development/Testing of SUMMIT: a Tool to Help Patients Manage Pain While Tapering Opioids
NCT04746833 ·Status: COMPLETED ·Phase: NA